Interview with Derek Williams, Vice President and General Manager, Vifor Pharma…
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
Address: Flughofstrasse 61, CH-8152 Glattbrugg,Germany
Tel: +41 58 851 80 00
Web: http://www.viforpharma.com/en/
Vifor Pharma is a fully integrated specialty pharma company within the Galenica Group. It unites all companies in the Pharma business sector of Galenica under one single umbrella organisation that researches, develops, produces and markets specific pharmaceutical products throughout the world.It is based on two main pillars: the business units Rx (prescription products) and Consumer Healthcare (OTC products). The operational basis of Vifor Pharma are lean and agile organisational structures. Vifor Pharma enjoys an increasing global presence. While the manufacture of all products is located in Switzerland and in the UK, the commercialisation is taken over by a wide network of affiliates and distributors all over the world.The business unit Vifor Pharma Consumer Healthcare manufactures and markets non-prescription products (OTC products) developed within Vifor Pharma or produced or sold under licence. Vifor Pharma plays a leading role in the area of non-prescription medicines, both in Switzerland and in selected countries of export. The focus of Vifor Pharma Consumer Health is on the development of own structures in key markets in Europe and on the continual optimisation of the product range through own developments and through the acquisition of products, licences and companies.
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation Reduction Act (IRA) has been introduced in the US while…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, critiques the draft EU Pharma Regulation…
Merck KGaA’s Marco Rauland and Kaushal Kishore examine how artificial intelligence and machine learning can best be applied in pharmaceutical pricing and market access. Noting the significant uptake of such…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, launches a critique of current pharmaceutical…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Germany-based pharma and healthcare services group Fresenius has had its share of challenges. After the group’s dialysis division, Fresenius Medical Care (FMC), was hit with a high rate of COVID-19…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
At the recent World Economic Forum in Davos, Chair of the Executive Board and CEO of Merck, Belén Garijo, speaking in a session on workforce transformation in the digital era,…
In response to a looming deficit of EUR 17 billion, Germany’s new Financial Stabilization of Statutory Health Insurance System Act (GKV-Finanzstabilisierungsgesetz, or GKV-FinStG) is aimed at containing costs in the…
The latest from German pharma, including Merck KGaA’s increased gamble on external innovation, Bayer’s focus supply chain stability, CatalYm’s EUR 50 million series C financing and Boehringer Ingelheim’s deal with…
A roundup of some of the biggest recent stories from German pharma, including the latest on beleaguered Bayer CEO Werner Baumann, Merck KGaA’s latest investments in France and Germany, and…
A snapshot of Germany, one of the European pharma hotspots featured in PharmaBoardroom’s latest report, InFigures: European Pharma Hotspots 2022. With the largest market value in Europe, Germany remains at…
See our Cookie Privacy Policy Here
